Does initiation of HIV antiretroviral therapy influence patterns of syringe lending among injection drug users?

Addictive Behaviors

Volumn 36, Issue 5, 2011, Pages 560-563

  Kuyper, Laura ^a   Milloy, M J ^a,b   Marshall, Brandon D L ^a,b   Zhang, Ruth ^b   Kerr, Thomas ^a,b   Montaner, Julio S G ^a,b   Wood, Evan ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Antiretroviral therapy; HIV; Injection drug use; Syringe lending

Indexed keywords

ANTIVIRUS AGENT; COCAINE; DIAMORPHINE; METHADONE;

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ABUSE PATTERN; DRUG USE; FEMALE; FOLLOW UP; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION DRUG USER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SYRINGE; TREATMENT DURATION;

ADULT; ANTI-RETROVIRAL AGENTS; CANADA; DRUG USERS; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEEDLE SHARING; PROSPECTIVE STUDIES; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 79951851827     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addbeh.2011.01.022     Document Type: Article

References (27)

1. Bouhnik A.D., Moatti J.P., Vlahov D., Gallais H., Dellamonica P., Obadia Y. Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users. Journal of Epidemiology and Community Health 2002, 56(5):349-353.
2. Clarke S.M., Mulcahy F.M. Antiretroviral therapy for drug users. International Journal of STD & AIDS 2000, 11(10):627-631.
3. Crepaz N., Hart T.A., Marks G. Highly active antiretroviral therapy and sexual risk behavior: A meta-analytic review. Journal of the American Medical Association 2004, 292(2):224-236.
4. DiClemente R.J., Funkhouser E., Wingood G., Fawal H., Holmberg S.D., Vermund S.H. Protease inhibitor combination therapy and decreased condom use among gay men. The Southern Medical Journal 2002, 95(4):421-425.
5. Harrison K.M., Song R., Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. Journal of Acquired Immune Deficiency Syndromes 2010, 53(1):124-130.
6. Joint United Nations Programme on HIV/AIDS Report on the global HIV/AIDS epidemic 2008 2008, UNAIDS, Geneva.
7. Kerr T., Small W., Buchner C., Zhang R., Li K., Montaner J., et al. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. American Journal of Public Health 2010, 100(8):1449-1453.
8. Latkin C.A., Buchanan A.S., Metsch L.R., Knight K., Latka M.H., Mizuno Y., et al. Predictors of sharing injection equipment by HIV-seropositive injection drug users. Journal of Acquired Immune Deficiency Syndromes 2008, 49(4):447-450.
9. Lima V.D., Geller J., Bangsberg D.R., Patterson T.L., Daniel M., Kerr T., et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007, 21(9):1175-1183.
10. Loughlin A., Metsch L., Gardner L., Anderson-Mahoney P., Barrigan M., Strathdee S. Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users. AIDS Care 2004, 16(4):485-500.
11. Maldonado G., Greenland S. Simulation study of confounder-selection strategies. American Journal of Epidemiology 1993, 138(11):923-936.
12. Marshall B.D.L., Kerr T., Shoveller J.A., Patterson T.L., Buxton J.A., Wood E. Homelessness and unstable housing associated with an increased risk of HIV and STI transmission among street-involved youth. Health & Place 2009, 15(3):753-760.
13. Marshall B.D.L., Milloy M.J., Kerr T., Zhang R., Montaner J.S., Wood E. No evidence of increased sexual risk behaviour after initiating antiretroviral therapy among people who inject drugs. AIDS 2010, 24(14):2271-2278.
14. Metsch L.R., Pereyra M., Purcell D.W., Latkin C.A., Malow R., Gomez C.A., et al. Correlates of lending needles/syringes among HIV-seropositive injection drug users. Journal of Acquired Immune Deficiency Syndromes 2007, 46(Suppl 2):S72-S79.
15. Miller M., Meyer L., Boufassa F., Persoz A., Sarr A., Robain M., et al. Sexual behavior changes and protease inhibitor therapy. SEROCO study group. AIDS 2000, 14(4):F33-F39.
16. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. The New England Journal of Medicine 1998, 338(13):853-860.
17. Rothman K.J., Greeland S., Lash T.L. Modern epidemiology 2008, Lippincott Williams & Wilkins, Philadelphia, PA. 3rd ed.
18. Tun W., Gange S.J., Vlahov D., Strathdee S.A., Celentano D.D. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users. Clinical Infectious Diseases 2004, 38(8):1167-1174.
19. Tyndall M.W., Craib K.J., Currie S., Li K., O'Shaughnessy M.V., Schechter M.T. Impact of HIV infection on mortality in a cohort of injection drug users. Journal of Acquired Immune Deficiency Syndromes 2001, 28(4):351-357.
20. Van de Ven P., Mao L., Fogarty A., Rawstorne P., Crawford J., Prestage G., et al. Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS 2005, 19(2):179-184.
21. Vlahov D., Celentano D.D. Access to highly active antiretroviral therapy for injection drug users: Adherence, resistance, and death. Cadernos de Saúde Pública 2006, 22(4):705-718.
22. Vlahov D., Safaien M., Lai S., Strathdee S.A., Johnson L., Sterling T., et al. Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. AIDS 2001, 15(17):2311-2316.
23. Wood E., Hogg R.S., Bonner S., Kerr T., Li K., Palepu A., et al. Staging for antiretroviral therapy among HIV-infected drug users. Journal of the American Medical Association 2004, 292(10):1175-1177.
24. Wood E., Hogg R.S., Lima V.D., Kerr T., Yip B., Marshall B.D.L., et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. Journal of the American Medical Association 2008, 300(5):550-554.
25. Wood E., Hogg R.S., Yip B., Harrigan P.R., O'Shaughnessy M.V., Montaner J.S. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350×10(9) cells/L. Annals of Internal Medicine 2003, 139(10):810-816.
26. Wood E., Kerr T., Hogg R.S., Zhang R., Tyndall M.W., Montaner J.S. Validity of self-reported antiretroviral therapy use among injection drug users. Journal of Acquired Immune Deficiency Syndromes 2006, 41(4):530-531.
27. Wood E., Kerr T., Tyndall M.W., Montaner J.S. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS 2008, 22(11):1247-1256.